| Entry |
|
|---|
| Name |
Enasidenib mesylate (USAN);
Idhifa (TN) |
|---|
| Product |
|
|---|
| Formula |
C19H17F6N7O. CH4SO3
|
|---|
| Exact mass |
569.128
|
|---|
| Mol weight |
569.4807
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Remark |
| Product (DG02837): | D11044<US> |
|
|---|
| Efficacy |
Antineoplastic, Isocitrate dehydrogenase 2 inhibitor |
|---|
| Disease |
Acute myeloid leukemia (IDH2 mutation positive) [DS: H00003] |
|---|
| Target |
|
|---|
| Pathway |
| hsa01210 | 2-Oxocarboxylic acid metabolism |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XX Other antineoplastic agents
L01XX59 Enasidenib
D11044 Enasidenib mesylate (USAN) <US>
USP drug classification [BR:br08302]
Antineoplastics
Antineoplastics, Other
Enasidenib
D11044 Enasidenib mesylate (USAN)
Target-based classification of drugs [BR:br08310]
Enzymes
Oxidoreductases (EC1)
Dehydrogenases
IDH2* [HSA_VAR:3418v1]
D11044 Enasidenib mesylate (USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11044
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11044
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D11044
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 38
1 N5x N 17.3187 -17.5290
2 C8y C 17.3187 -18.9314
3 N5x N 18.5107 -19.6325
4 C8y C 19.7027 -18.9314
5 N5x N 19.7027 -17.5290
6 C8y C 18.5107 -16.8279
7 C8y C 18.5107 -15.4256
8 C8x C 19.7027 -14.7244
9 C8x C 19.7027 -13.3221
10 C8x C 18.5107 -12.6209
11 C8y C 17.3187 -13.3221
12 N5x N 17.3187 -14.7244
13 C1d C 16.0566 -12.6209
14 X F 14.8646 -11.9198
15 X F 15.3554 -13.8129
16 X F 16.7578 -11.3588
17 N1b N 20.9647 -19.6325
18 C8y C 22.1567 -18.9314
19 C8x C 23.3487 -19.6325
20 C8x C 24.6108 -18.9314
21 N5x N 24.6108 -17.5290
22 C8y C 23.4188 -16.8279
23 C8x C 22.1567 -17.5290
24 C1d C 23.4188 -15.4256
25 X F 23.4188 -14.0232
26 X F 22.0165 -15.4256
27 X F 24.8211 -15.4256
28 N1b N 16.0566 -19.6325
29 C1b C 14.8646 -18.9314
30 C1d C 13.6727 -19.6325
31 C1a C 12.4807 -18.9314
32 O1a O 13.6727 -21.0349
33 C1a C 12.4807 -20.3337
34 S4a S 28.3500 -18.4100
35 O1d O 26.9500 -18.4100
36 C1a C 29.7500 -18.4100
37 O1d O 28.3500 -19.8100
38 O1d O 28.3500 -17.0100
BOND 39
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 6 7 1
8 7 8 2
9 8 9 1
10 9 10 2
11 10 11 1
12 11 12 2
13 7 12 1
14 11 13 1
15 13 14 1
16 13 15 1
17 13 16 1
18 4 17 1
19 17 18 1
20 18 19 2
21 19 20 1
22 20 21 2
23 21 22 1
24 22 23 2
25 18 23 1
26 22 24 1
27 24 25 1
28 24 26 1
29 24 27 1
30 2 28 1
31 28 29 1
32 29 30 1
33 30 31 1
34 30 32 1
35 30 33 1
36 34 35 1
37 34 36 1
38 34 37 2
39 34 38 2
|
|---|
